Drug updated on 11/13/2023
|Inhalation spray (oral: 2.5 mcg)
|Long-acting beta2-adrenergic agonist (LABA)
|Ongoing and Completed Studies
- The long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
Product Monograph / Prescribing Information
|Striverdi Respimat (olodaterol) Prescribing Information.
|Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT
Systematic Reviews / Meta-Analyses
|Comparisons of exacerbations and mortality among LAMA/LABA combinations in stable chronic obstructive pulmonary disease: systematic review and Bayesian network meta-analysis.
|Relationship of inhaled long-acting bronchodilators with cardiovascular outcomes among patients with stable COPD: a meta-analysis and systematic review of 43 randomized trials.
|International Journal of Chronic Obstructive Pulmonary Disease
|Once daily long‐acting beta2‐agonists and long‐acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease.
|Cochrane Database of Systematic Reviews
|LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review.
|International Journal of COPD
Clinical Practice Guidelines
|Romanian clinical guideline for diagnosis and treatment of COPD.
|Journal of International Medical Research
|Chronic obstructive pulmonary disease – adult – inpatient/ambulatory/ emergency department clinical practice guideline.